PHARMACYTE BIOTECH, INC. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent
PHARMACYTE BIOTECH, INC. (PMCB) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent of -$615 for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2026-07-31 was -$615.00, a 600.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2026-01-31 was $2.59K.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2025-10-31 was -$381.00, a 724.59% decline year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2025-07-31 was $123.00, a 32.79% decline year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2026 was $3.07K.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2025 was -$358.00.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2024 was -$508.00.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2023 was -$7.25K, a 256.67% decline from fiscal 2022.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$615.00 10-Q · filed 2026-09-14 | |||
| 2026-04-30 | $3.07K 10-K · filed 2026-07-29 | |||
| 2026-01-31 | $2.59K 10-Q · filed 2026-03-17 | $2.21K derived: sum of 2 quarters · filed 2026-03-17 | $2.33K derived: sum of 3 quarters · filed 2026-09-14 | |
| 2025-10-31 | -$381.00 10-Q · filed 2026-03-17 | -$258.00 derived: sum of 2 quarters · filed 2026-09-14 | ||
| 2025-07-31 | $123.00 10-Q · filed 2026-09-14 | |||
| 2025-04-30 | -$358.00 10-K · filed 2026-07-29 | |||
| 2025-01-31 | -$1.22K 10-Q · filed 2026-03-17 | -$1.16K derived: sum of 2 quarters · filed 2026-03-17 | -$975.00 derived: sum of 3 quarters · filed 2026-03-17 | |
| 2024-10-31 | $61.00 10-Q · filed 2026-03-17 | $244.00 derived: sum of 2 quarters · filed 2026-03-17 | ||
| 2024-07-31 | $183.00 10-Q · filed 2026-03-17 | |||
| 2024-04-30 | -$508.00 10-K · filed 2025-08-11 | |||
| 2024-01-31 | $1.07K 10-Q · filed 2025-03-17 | -$521.00 derived: sum of 2 quarters · filed 2025-03-17 | -$70.00 derived: sum of 3 quarters · filed 2025-03-17 | -$5.35K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | -$1.59K 10-Q · filed 2025-03-17 | -$1.14K derived: sum of 2 quarters · filed 2025-03-17 | -$6.42K derived: sum of 3 quarters · filed 2025-03-17 | -$8.97K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-07-31 | $451.00 10-Q · filed 2025-03-17 | -$4.83K derived: sum of 2 quarters · filed 2025-03-17 | -$7.38K derived: sum of 3 quarters · filed 2025-03-17 | -$8.10K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-04-30 | -$5.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | -$7.83K derived: sum of 2 quarters · filed 2024-08-13 | -$8.55K derived: sum of 3 quarters · filed 2024-08-13 | -$7.25K 10-K · filed 2024-08-13 |
| 2023-01-31 | -$2.55K 10-Q · filed 2024-03-18 | -$3.27K derived: sum of 2 quarters · filed 2024-03-18 | -$1.97K 10-Q · filed 2023-03-16 | $1.57K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$720.00 10-Q · filed 2024-03-18 | $584.00 10-Q · filed 2022-12-14 | $4.13K derived: sum of 3 quarters · filed 2024-03-18 | $3.92K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-07-31 | $1.30K 10-Q · filed 2024-03-18 | $4.85K derived: sum of 2 quarters · filed 2024-03-18 | $4.64K derived: sum of 3 quarters · filed 2024-03-18 | $7.54K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-04-30 | $3.54K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-31 | $3.33K derived: sum of 2 quarters · filed 2023-07-31 | $6.24K derived: sum of 3 quarters · filed 2023-07-31 | $4.63K 10-K · filed 2023-07-31 |
| 2022-01-31 | -$210.00 10-Q · filed 2023-03-16 | $2.70K derived: sum of 2 quarters · filed 2023-03-16 | $1.08K 10-Q · filed 2023-03-16 | $1.71K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-10-31 | $2.91K 10-Q · filed 2023-03-16 | $1.29K 10-Q · filed 2022-12-14 | $1.92K derived: sum of 3 quarters · filed 2023-03-16 | $2.79K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-07-31 | -$1.61K 10-Q · filed 2023-03-16 | -$982.00 derived: sum of 2 quarters · filed 2023-03-16 | -$113.00 derived: sum of 3 quarters · filed 2023-03-16 | $2.74K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-04-30 | $633.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-28 | $1.50K derived: sum of 2 quarters · filed 2022-07-28 | $4.35K derived: sum of 3 quarters · filed 2022-07-28 | $1.33K 10-K · filed 2022-07-28 |
| 2021-01-31 | $869.00 10-Q · filed 2022-03-15 | $3.72K derived: sum of 2 quarters · filed 2022-03-15 | $694.00 10-Q · filed 2022-03-15 | $6.06K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-10-31 | $2.85K 10-Q · filed 2021-12-14 | -$175.00 10-Q · filed 2021-12-14 | $5.19K derived: sum of 3 quarters · filed 2021-12-14 | $4.59K derived: sum of 4 quarters · filed 2021-12-14 |
| 2020-07-31 | $2.68K 10-Q · filed 2021-09-14 | $2.34K derived: sum of 2 quarters · filed 2021-09-14 | $1.74K derived: sum of 3 quarters · filed 2021-09-14 | $1.67K derived: sum of 4 quarters · filed 2021-09-14 |
| 2020-04-30 | -$337.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-10 | -$939.00 derived: sum of 2 quarters · filed 2021-08-10 | -$1.00K derived: sum of 3 quarters · filed 2021-08-10 | -$7.87K 10-K · filed 2021-08-10 |
| 2020-01-31 | -$602.00 10-Q · filed 2021-03-12 | -$668.00 derived: sum of 2 quarters · filed 2021-03-12 | -$7.53K 10-Q · filed 2021-03-12 | -$12.88K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-10-31 | -$66.00 10-Q · filed 2020-12-11 | -$6.93K 10-Q · filed 2020-12-11 | -$12.27K derived: sum of 3 quarters · filed 2020-12-11 | -$8.73K derived: sum of 4 quarters · filed 2020-12-11 |
| 2019-07-31 | -$6.86K 10-Q · filed 2020-09-11 | -$12.21K derived: sum of 2 quarters · filed 2020-09-11 | -$8.66K derived: sum of 3 quarters · filed 2020-09-11 | -$14.72K derived: sum of 4 quarters · filed 2020-09-11 |
| 2019-04-30 | -$5.35K derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-13 | -$1.80K derived: sum of 2 quarters · filed 2020-08-13 | -$7.86K derived: sum of 3 quarters · filed 2020-08-13 | -$9.13K 10-K · filed 2020-08-13 |
| 2019-01-31 | $3.54K 10-Q · filed 2020-03-13 | -$2.51K derived: sum of 2 quarters · filed 2020-03-13 | -$3.79K 10-Q · filed 2020-03-13 | -$8.99K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-10-31 | -$6.06K 10-Q · filed 2020-03-13 | -$7.33K 10-Q · filed 2019-12-23 | -$12.53K derived: sum of 3 quarters · filed 2020-03-13 | -$14.04K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-07-31 | -$1.27K 10-Q · filed 2020-03-13 | -$6.47K derived: sum of 2 quarters · filed 2020-03-13 | -$7.98K derived: sum of 3 quarters · filed 2020-03-13 | -$7.74K derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-04-30 | -$5.20K derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-13 | -$6.71K derived: sum of 2 quarters · filed 2019-08-13 | -$6.46K derived: sum of 3 quarters · filed 2019-08-13 | -$6.45K 10-K · filed 2019-08-13 |
| 2018-01-31 | -$1.51K 10-Q · filed 2019-03-14 | -$1.26K derived: sum of 2 quarters · filed 2019-03-14 | -$1.24K 10-Q · filed 2019-03-14 | -$3.99K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-10-31 | $247.00 10-Q · filed 2019-03-14 | -$1.47K 10-Q · filed 2018-12-14 | -$2.48K derived: sum of 3 quarters · filed 2019-03-14 | -$2.19K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-07-31 | -$1.72K 10-Q · filed 2019-03-14 | -$2.73K derived: sum of 2 quarters · filed 2019-03-14 | -$2.43K derived: sum of 3 quarters · filed 2019-03-14 | -$2.82K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-04-30 | -$1.01K derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-20 | -$714.00 derived: sum of 2 quarters · filed 2018-07-20 | -$1.10K derived: sum of 3 quarters · filed 2018-07-20 | $930.00 10-K · filed 2018-07-20 |
| 2017-01-31 | $300.00 10-Q · filed 2018-03-19 | -$90.00 derived: sum of 2 quarters · filed 2018-03-19 | $1.94K 10-Q · filed 2018-03-19 | -$3.79K derived: sum of 4 quarters · filed 2018-03-19 |
| 2016-10-31 | -$390.00 10-Q · filed 2017-12-14 | -$1.64K 10-Q · filed 2017-12-14 | -$4.09K derived: sum of 3 quarters · filed 2017-12-14 | -$3.89K derived: sum of 4 quarters · filed 2017-12-14 |
| 2016-07-31 | -$1.25K 10-Q · filed 2017-09-13 | -$3.70K derived: sum of 2 quarters · filed 2017-09-13 | -$3.50K derived: sum of 3 quarters · filed 2017-09-13 | -$3.53K derived: sum of 4 quarters · filed 2017-09-13 |
| 2016-04-30 | -$2.44K derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-27 | -$2.24K derived: sum of 2 quarters · filed 2017-07-27 | -$2.28K derived: sum of 3 quarters · filed 2017-07-27 | -$656.00 10-K · filed 2017-07-27 |
| 2016-01-31 | $202.00 10-Q · filed 2017-03-13 | $168.00 derived: sum of 2 quarters · filed 2017-03-13 | $1.79K 10-Q · filed 2017-03-13 | $9.00 derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-10-31 | -$34.00 10-Q · filed 2016-12-02 | $1.59K 10-Q · filed 2016-12-02 | -$193.00 derived: sum of 3 quarters · filed 2016-12-02 | -$193.00 derived: sum of 4 quarters · filed 2016-12-02 |
| 2015-07-31 | -$1.62K 10-Q · filed 2016-09-06 | -$159.00 derived: sum of 2 quarters · filed 2016-09-06 | -$159.00 derived: sum of 3 quarters · filed 2016-09-06 | -$159.00 derived: sum of 4 quarters · filed 2016-09-06 |
| 2015-04-30 | $1.46K derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | $1.46K derived: sum of 2 quarters · filed 2016-07-29 | $1.46K derived: sum of 3 quarters · filed 2016-07-29 | $1.46K 10-K · filed 2016-07-29 |
| 2015-01-31 | $0.00 10-Q · filed 2016-03-08 | $0.00 derived: sum of 2 quarters · filed 2016-03-08 | $0.00 10-Q · filed 2016-03-08 | |
| 2014-10-31 | $0.00 10-Q/A · filed 2016-01-19 | $0.00 10-Q/A · filed 2016-01-19 | ||
| 2014-07-31 | $0.00 10-Q/A · filed 2016-01-19 | |||
| 2014-04-30 | $0.00 10-K · filed 2016-07-29 | |||
| 2013-04-30 | $0.00 10-K/A · filed 2016-01-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |